- Home
- RDN vs GRFS Comparison
RDN vs GRFS Comparison
Compare RDN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDN | GRFS |
|---|---|---|
| Founded | 1977 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.2B |
| IPO Year | 2008 | 2008 |
Fundamental Metrics
Financial Performance| Metric | RDN | GRFS |
|---|---|---|
| Price | $35.36 | $7.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $40.67 | $10.15 |
| AVG Volume (30 Days) | ★ 772.6K | 371.0K |
| Earning Date | 05-06-2026 | 07-28-2022 |
| Dividend Yield | ★ 2.73% | 1.80% |
| EPS Growth | ★ 5.61 | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $1,197,084,000.00 | N/A |
| Revenue This Year | N/A | $4.49 |
| Revenue Next Year | $2.66 | $6.42 |
| P/E Ratio | $20.47 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $31.50 | $6.96 |
| 52 Week High | $41.05 | $10.23 |
Technical Indicators
Market Signals| Indicator | RDN | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 38.49 |
| Support Level | $31.87 | $7.33 |
| Resistance Level | $37.34 | $8.36 |
| Average True Range (ATR) | 0.62 | 0.14 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 20.51 | 3.17 |
Price Performance
Historical ComparisonAbout RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.